Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKinsey
Medtronic
Harvard Business School
Johnson and Johnson

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for BAY1834845


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug BAY1834845?

BAY1834845 is an investigational drug.

There have been 4 clinical trials for BAY1834845. The most recent clinical trial was a Phase 1 trial, which was initiated on June 28th 2021.

The most common disease conditions in clinical trials are Psoriasis, Arthritis, Rheumatoid, and Arthritis. The leading clinical trial sponsors are Bayer and [disabled in preview].

There are three US patents protecting this investigational drug and one hundred international patents.

Recent Clinical Trials for BAY1834845
TitleSponsorPhase
A Trial to Learn How BAY1834845 and BAY1830839 Affect Inflammation When Taken by Mouth Twice a Day for 7 Days in a Row in Healthy Male ParticipantsBayerPhase 1
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With PsoriasisBayerPhase 1
Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With MethotrexateBayerPhase 1

See all BAY1834845 clinical trials

Clinical Trial Summary for BAY1834845

Top disease conditions for BAY1834845
Top clinical trial sponsors for BAY1834845

See all BAY1834845 clinical trials

US Patents for BAY1834845

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BAY1834845 ⤷  Try it Free Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) ⤷  Try it Free
BAY1834845 ⤷  Try it Free Polymorphic form of N-{6-(hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6- -(trifluoromethyl)pyridine-2-carboxamide Bayer Pharma Aktiengesellschaft (Berlin, DE) ⤷  Try it Free
BAY1834845 ⤷  Try it Free Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs Bayer Pharma Aktiengesellschaft (Berlin, DE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BAY1834845

Drugname Country Document Number Estimated Expiration Related US Patent
BAY1834845 Argentina AR102827 2034-11-26 ⤷  Try it Free
BAY1834845 Australia AU2015352603 2034-11-26 ⤷  Try it Free
BAY1834845 Australia AU2020200979 2034-11-26 ⤷  Try it Free
BAY1834845 Brazil BR112017011005 2034-11-26 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
McKinsey
Medtronic
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.